Tamibarotene

他米巴罗汀

Report date: 2025/10/24 17:59:39
NMEFirst In Class

Base Information

Drug NameTamibarotene
Drug Alias Name他来巴罗汀TamibarotenumTamibarotenoTamibarotene (Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical)OP-01 (Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical) +[22] 
ClassificationSmall molecules
Mechanisms of ActionRetinoic acid receptor alpha agonistsRetinoic acid receptor beta agonists
TargetsRetinoic acid receptor alphaRetinoic acid receptor beta
Therapy Area/IndicationsMyelodysplastic SyndromesLupus NephritisAlzheimer Disease +[9] 
Global Approved IndicationsLeukemia, Promyelocytic, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2005/04/11
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSyros Pharmaceuticals IncNagoya UniversityHangzhou Rongli Medicine Technology Co Ltd +[4] 
Inactive CompaniesZeria PharmaceuticalKinki UniversitySt Marianna University School Of Medicine +[6] 
Active IndicationsMyelodysplastic SyndromesPancreatic NeoplasmsLeukemia, Promyelocytic, Acute
Inactive IndicationsLupus NephritisAlzheimer DiseaseCrohn Disease +[6] 

Other Information

ATC CodeL01X
Related LinksWikipediaDrugBankKEGG